Propranolol or Beta-Blockers for Cerebral Cavernous Malformation: a Systematic Review and Meta-analysis of Literature in Both Preclinical and Clinical Studies.
Beta-blockers
Cavernoma
Cerebral cavernous malformation
Propranolol
Journal
Translational stroke research
ISSN: 1868-601X
Titre abrégé: Transl Stroke Res
Pays: United States
ID NLM: 101517297
Informations de publication
Date de publication:
19 Oct 2023
19 Oct 2023
Historique:
received:
22
08
2023
accepted:
05
10
2023
revised:
04
10
2023
medline:
20
10
2023
pubmed:
20
10
2023
entrez:
19
10
2023
Statut:
aheadofprint
Résumé
Cerebral cavernous malformation (CCM), either sporadic or familial, is a devastating vascular malformation affecting the central nervous system that can present with intracerebral hemorrhage, seizure, and new focal neurologic deficits resulting in substantial morbidity and mortality. To date, there is no effective evidence-based preventive regimen. There have been several preclinical and clinical studies investigating the potential mechanisms and benefits of beta-blockers, especially on propranolol. We aimed to conduct a systematic review on the published literature investigating the use of beta-blockers in the treatment of CCM, including both preclinical and clinical studies between 2008 and 2023 using public databases. A total of 2 preclinical studies and 6 clinical studies met the inclusion/exclusion criteria and were included. Data was extracted and synthesized from 5 clinical studies for meta-analysis. The meta-analysis failed to demonstrate a statistically significant protective effect of beta-blockers in preventing intracerebral hemorrhage or developing focal neurologic deficits in subjects with CCM (overall effect = 0.78 (0.20, 3.11), p = 0.73). Overall, there was a paucity of high quality clinical trials, partially due to limited cases of CCM. Addressing this gap may require collaborative efforts at a national or international level. In this review, we summarized all barriers and opportunities on this topic. Additionally, we proposed establishing an evidence-based approach on the use of beta-blockers in preventing recurrent hemorrhage and focal neurological deficits in patients with CCM.
Identifiants
pubmed: 37857790
doi: 10.1007/s12975-023-01199-5
pii: 10.1007/s12975-023-01199-5
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Gross BA, Lin N, Du R, Day AL. The natural history of intracranial cavernous malformations. Neurosurg Focus. 2011;30(6):E24.
doi: 10.3171/2011.3.FOCUS1165
pubmed: 21631226
Goldstein HE, Solomon RA. Epidemiology of cavernous malformations. Handb Clin Neurol. 2017;143:241–7.
doi: 10.1016/B978-0-444-63640-9.00023-0
pubmed: 28552146
Morris Z, et al. Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2009;339: b3016.
doi: 10.1136/bmj.b3016
pubmed: 19687093
pmcid: 2728201
Awad IA, Robinson JR Jr, Mohanty S, Estes ML. Mixed vascular malformations of the brain: clinical and pathogenetic considerations. Neurosurg. 1993;33(2):179–88. https://doi.org/10.1227/00006123-199308000-00001 .
doi: 10.1227/00006123-199308000-00001
Jehi LE, et al. Cerebral cavernous malformations in the setting of focal epilepsies: pathological findings, clinical characteristics, and surgical treatment principles. Acta Neuropathol. 2014;128(1):55–65.
doi: 10.1007/s00401-014-1294-y
pubmed: 24831066
Gomez-Paz S, et al. Role of aspirin and statin therapy in patients with cerebral cavernous malformations. J Clin Neurosci. 2020;78:246–51.
doi: 10.1016/j.jocn.2020.04.012
pubmed: 32340842
Drolet BA, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131(1):128–40.
doi: 10.1542/peds.2012-1691
pubmed: 23266923
pmcid: 3529954
Léauté-Labrèze C, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372(8):735–46.
doi: 10.1056/NEJMoa1404710
pubmed: 25693013
de Morton NA. The PEDro scale is a valid measure of the methodological quality of clinical trials: a demographic study. Aust J Physiother. 2009;55(2):129–33.
doi: 10.1016/S0004-9514(09)70043-1
pubmed: 19463084
Fisher M, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40(6):2244–50.
doi: 10.1161/STROKEAHA.108.541128
pubmed: 19246690
pmcid: 2888275
Zuurbier SM, et al. Association between beta-blocker or statin drug use and the risk of hemorrhage from cerebral cavernous malformations. Stroke. 2022;53(8):2521–7.
doi: 10.1161/STROKEAHA.121.037009
pubmed: 35410492
pmcid: 9311291
Previch L, Lanzino G, Brown RD Jr, Flemming KD. The influence of select medications on prospective hemorrhage risk in patients with spinal or cerebral cavernous malformations. World Neurosurg. 2022;163:e678–83.
doi: 10.1016/j.wneu.2022.03.101
pubmed: 35364298
Lanfranconi S, et al. Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial. Lancet Neurol. 2023;22(1):35–44.
doi: 10.1016/S1474-4422(22)00409-4
pubmed: 36403580
Santos AN, et al. Medication intake and hemorrhage risk in patients with familial cerebral cavernous malformations. J Neurosurg. 2022;1–7. https://doi.org/10.3171/2022.1.JNS212724 .
Goldberg J, et al. Bleeding risk of cerebral cavernous malformations in patients on beta-blocker medication: a cohort study. J Neurosurg. 2018;1-6. https://doi.org/10.3171/2017.12.JNS172404 .
Chen B, et al. Effects of medication intake on the risk of hemorrhage in patients with sporadic cerebral cavernous malformations. Front Neurol. 2022;13:1010170.
doi: 10.3389/fneur.2022.1010170
pubmed: 36686509
Oldenburg J, et al. Propranolol reduces the development of lesions and rescues barrier function in cerebral cavernous malformations: a preclinical study. Stroke. 2021;52(4):1418–27.
doi: 10.1161/STROKEAHA.120.029676
pubmed: 33618555
Li W, et al. Propranolol inhibits cavernous vascular malformations by beta1 adrenergic receptor antagonism in animal models. J Clin Invest. 2021;131(3):e144893. https://doi.org/10.1172/JCI144893 .
Hoffman JE, et al. Successful treatment of hemorrhagic brainstem cavernous malformation with hematoma evacuation and postoperative propranolol. Childs Nerv Syst. 2020;36(9):2109–12.
doi: 10.1007/s00381-020-04588-5
pubmed: 32303833
Zabramski JM, Kalani MYS, Filippidis AS, Spetzler RF. Propranolol treatment of cavernous malformations with symptomatic hemorrhage. World Neurosurg. 2016;88:631–9.
doi: 10.1016/j.wneu.2015.11.003
pubmed: 26578351
Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol. 2010;163(2):269–74.
doi: 10.1111/j.1365-2133.2010.09848.x
pubmed: 20456345
Ji Y, et al. The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action. Br J Dermatol. 2015;172(1):24–32.
doi: 10.1111/bjd.13388
pubmed: 25196392